Powder: -20°C for 3 years | In solvent: -80°C for 1 year
MF-766 is a highly potent, selective and orally active EP4 antagonist with a Ki of 0.23 nM. It behaves as a full antagonist with an IC50 of 1.4 nM (shifted to 1.8 nM in the presence of 10% HS) in the functional assay. It can be used for cancer and inflammation diseases research[1][2].
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 74.00 | |
5 mg | In stock | $ 178.00 | |
10 mg | In stock | $ 289.00 | |
25 mg | In stock | $ 572.00 | |
50 mg | In stock | $ 822.00 | |
100 mg | In stock | $ 1,130.00 | |
500 mg | In stock | $ 2,280.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 193.00 |
Description | MF-766 is a highly potent, selective and orally active EP4 antagonist with a Ki of 0.23 nM. It behaves as a full antagonist with an IC50 of 1.4 nM (shifted to 1.8 nM in the presence of 10% HS) in the functional assay. It can be used for cancer and inflammation diseases research[1][2]. |
Targets&IC50 | EP4:0.23 nM (Ki) |
In vitro | MF-766, at concentrations ranging from 0.01 to 10 μM and pretreated for 1 hour before being stimulated with 50 ng/mL IL-2—both with and without 0.33 μM PGE2 for 18 hours—effectively reverses the suppression of IFN-γ secretion in human NK cells caused by PGE2. Importantly, the viability of NK cells remains unaffected by MF-766[2]. |
In vivo |
MF-766 (oral gavage; 30 mg/kg; once daily; 21 days) exhibits TGI% of 49% in CT26 tumor model. But it does not exhibits significant difference in EMT6 and 4T1 tumor model[2]. MF-766 (oral gavage; 30 mg/kg combination with anti-PD-1 mDX400; once daily; 21 days; q4dx8) shows potent anti-tumor activities in different preclinical models. The % of TGI are 89%, 66% and 40%, respectively in CT26 tumor, EMT6 and 4T1 tumor model[2]. |
Molecular Weight | 478.46 |
Formula | C27H21F3N2O3 |
CAS No. | 1050656-06-8 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 50 mg/mL (104.50 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
MF-766 1050656-06-8 GPCR/G Protein Immunology/Inflammation Prostaglandin Receptor EP4 arthritis inflammation disease AIA inhibit anti-tumor MF766 MF 766 Inhibitor cancer inhibitor